HER2状态预测 upfront AI 获益:TRANS-AIOG 对 ATAC、BIG 1-98 和 TEAM 中12129例患者的 Meta 分析(中心实验室确定 HER2)
该 Meta 分析纳入 ATAC、BIG 1-98 和 TEAM 三项 III 期试验共12129例患者,按前瞻性统计计划分析辅助内分泌治疗前2-3年内 HER2 状态与 AI 对比他莫昔芬的交互作用。多因素分析显示交互作用 HR=1.61(95%CI 1.01-2.57,p<0.05);HER2 阴性组 AI 对比他莫昔芬 HR=0.70(95%CI 0.56-0.87),HER2 阳性组 HR=1.13(95%CI 0.75-1.71)。
要点
- HER2状态与AI对比他莫昔芬治疗存在显著交互作用,交互作用HR=1.61(95%CI 1.01-2.57,p<0.05)。
- HER2阴性组从AI对比他莫昔芬中获得更大获益,HR=0.70(95%CI 0.56-0.87)。
- HER2阳性组AI对比他莫昔芬HR=1.13(95%CI 0.75-1.71),获益未优于或略差于他莫昔芬。
核心结论
- 患者水平数据 Meta 分析显示,在辅助内分泌治疗前2-3年内,HER2状态与AI对比他莫昔芬治疗之间存在显著交互作用。
- HER2阴性癌症患者接受 upfront AI 而非他莫昔芬时远处复发结局改善,而HER2阳性癌症患者在前2-3年内结局不优于或略差于他莫昔芬。
- HER2阳性癌症/事件数量少可能解释三项试验中HER2阳性组的大部分异质性,其他原因(可能与AI之间细微差异有关)不能排除,需进一步探索。
研究设计与样本
- 遵循前瞻性设计的统计分析计划,收集比较AI与他莫昔芬辅助内分泌治疗前2-3年的三项III期试验(ATAC、BIG 1-98和TEAM)的患者数据。
- 进行按标志物分层的治疗分析,分析前2-3年治疗期删失的远处无复发生存间期,针对HER2状态×AI对比他莫昔芬治疗,以回答AI「upfront」对比「switch」策略疗效的临床问题。
主要发现
- 三项试验前瞻性计划的患者水平数据 Meta 分析显示,多因素分析中治疗(AI对比他莫昔芬)与标志物(HER2)交互作用显著,交互作用HR=1.61(95%CI 1.01-2.57;p<0.05)。
- 试验间异质性未达统计学显著。
- HER2阴性组从AI对比他莫昔芬中获得的获益(HR=0.70,95%CI 0.56-0.87)大于HER2阳性组(HR=1.13,95%CI 0.75-1.71)。
- 三项试验中HER2阳性病例数少(n=1092)且远处复发数少(n=111),可能解释试验间异质性。
关键数值与推荐
- 交互作用HR=1.61(95%CI 1.01-2.57;p<0.05)。
- HER2阴性组AI对比他莫昔芬HR=0.70(95%CI 0.56-0.87)。
- HER2阳性组AI对比他莫昔芬HR=1.13(95%CI 0.75-1.71)。
- 三项试验中HER2阳性病例n=1092,远处复发n=111。
局限性
- HER2阳性病例数少(n=1092)且远处复发数少(n=111),可能解释试验间异质性。
- HER2阳性组在三项试验中存在较大程度异质性,其他原因(可能与AI之间细微差异有关)不能排除,需进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A meta-analysis of the effects of HER2 status, specifically within the first 2-3 years of adjuvant endocrine therapy, has the potential to inform patient selection for upfront aromatase inhibitor (AI) therapy or switching strategy tamoxifen followed by AI. The pre-existing standardisation of methodology for HER2 (immunohistochemistry/fluorescence in situ hybridization) facilitates analysis of existing data for this key marker. METHODS: Following a prospectively designed statistical analysis plan, patient data from 3 phase III trials Arimidex, Tamoxifen, Alone or in Combination Trial (ATAC), Breast International Group (BIG) 1-98 and Tamoxifen Exemestane Adjuvant Multicentre Trial (TEAM)] comparing an AI to tamoxifen during the first 2-3 years of adjuvant endocrine treatment were collected and a treatment-by-marker analysis of distant recurrence-free interval-censored at 2-3 years treatment - for HER2 status × AI versus tamoxifen treatment was performed to address the clinical question relating to efficacy of 'upfront' versus 'switch' strategies for AIs. RESULTS: A prospectively planned, patient-level data meta-analysis across 3 trials demonstrated a significant treatment (AI versus tamoxifen) by marker (HER2) interaction in a multivariate analysis; (interaction hazard ratio [HR] = 1.61, 95% CI 1.01-2.57; p < 0.05). Heterogeneity between trials did not reach statistical significance. The HER2 negative (HER2-ve) group gained greater benefit from AI versus tamoxifen (HR = 0.70, 95% CI 0.56-0.87) than the HER2-positive (HER2+ve) group (HR = 1.13, 95% CI 0.75-1.71). However, the small number of HER2+ve cases (n = 1092 across the 3 trials) and distant recurrences (n = 111) may explain heterogeneity between trials. CONCLUSIONS: A patient-level data meta-analysis demonstrated a significant interaction between HER2 status and treatment with AI versus tamoxifen in the first 2-3 years of adjuvant endocrine therapy. Patients with HER2-ve cancers experienced improved outcomes (distant relapse) when treated with upfront AI rather than tamoxifen, whilst patients with HER2+ve cancers fared no better or slightly worse in the first 2-3 years. However, the small number of HER2+ve cancers/events may explain a large degree of heterogeneity in the HER2+ve groups across all 3 trials. Other causes, perhaps related to subtle differences between AIs, cannot be excluded and warrant further exploration.
引用
- Bartlett JMS, Ahmed I, Regan MM, et al. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. Eur J Cancer. 2017. PMID: 28494403. doi:10.1016/j.ejca.2017.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。